Skip to main content

Latest posts

INDUCE Study Wins ‘Jewel In The Crown’ Presentation At The College Of Podiatry Annual Conference And Exhibition In Glasgow

INDUCE Study Wins ‘Jewel In The Crown’ Presentation At The College Of Podiatry Annual Conference And Exhibition In Glasgow

Posted on 14 December 2016 by Richard Haggerty

I presented at The College of Podiatry annual conference and exhibition in Glasgow on the 17th Nov 2016. The INDUCE study was selected as the Jewel in the Crown presentation from […]

UK Society for Behavioural Medicine (UKSBM): 12th Annual Conference in Cardiff

UK Society for Behavioural Medicine (UKSBM): 12th Annual Conference in Cardiff

Posted on 14 December 2016 by Mark Kelson

The 12th UKSBM conference, organised by a team from the South East Wales Trials Unit (SEWTU) based in the Centre for Trials Research at Cardiff University, lead by Dr Rachel […]

RDCS Annual Event 2016: Increasing Research Capacity in Wales

RDCS Annual Event 2016: Increasing Research Capacity in Wales

Posted on 20 October 2016 by Mark Kelson

The Research Design and Conduct Service (RDCS) South East Wales held its annual showcase event recently. This is our longest running event, now in its sixth year, and it has […]

Developing Research Priorities in Care Homes into Collaborative Projects

Developing Research Priorities in Care Homes into Collaborative Projects

Posted on 22 August 2016 by Victoria Shepherd

A recent workshop organised by the Centre for Trials Research and PRIME Centre Wales brought together experts in Wales with an interest in care for the older person, so they could begin […]

SIDE-PRO Study: A Measure To Identify Treatment Side Effects In Adults With An Intellectual Disability And Epilepsy

SIDE-PRO Study: A Measure To Identify Treatment Side Effects In Adults With An Intellectual Disability And Epilepsy

Posted on 4 August 2016 by Andrea Meek

Identifying treatment Side effects in adults with an Intellectual Disability and Epilepsy: Development of Patient-Reported Outcome Measure for identification of Anti-Epileptic Drug side effects (SIDE-PRO) Study Background We are conducting […]

Inside The Phoenix Project: Sharing Statistical Methods With The University of Namibia

Inside The Phoenix Project: Sharing Statistical Methods With The University of Namibia

Posted on 6 June 2016 by Mark Kelson

As part of Cardiff University’s Phoenix Project, senior statistician and Research Design and Conduct Service (RDCS) consultant Dr Mark Kelson from the Centre for Trials Research has just returned from […]

Methods: An Emerging Centre for Trials Research Theme

Methods: An Emerging Centre for Trials Research Theme

Posted on 26 April 2016 by Mark Kelson

It has been said that humans make an average of 35,000 decisions every day*. This seems like an underestimate when working in the Centre for Trials Research. Being part of a […]

SCOPE2: Can Increasing The Dose Of Radiotherapy Improve Outcomes In Patients With Oesophageal Cancer?

SCOPE2: Can Increasing The Dose Of Radiotherapy Improve Outcomes In Patients With Oesophageal Cancer?

Posted on 26 April 2016 by Ruby Ray

SCOPE2 is a randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemo-radiation with an embedded Phase II trial for patients with […]

MID-Frail And What A 102 Year Old Study Participant Is Teaching Us About What’s Possible

MID-Frail And What A 102 Year Old Study Participant Is Teaching Us About What’s Possible

Posted on 18 April 2016 by Mark Kelson

The MID-Frail study investigates a complex intervention comprising dietary and education advice, physical activity and optimized care for this highly under-researched population.  The Centre for Trials Research is responsible for the […]

PIN: A Trial Looking At Olaparib For Non Small Cell Lung Cancer

PIN: A Trial Looking At Olaparib For Non Small Cell Lung Cancer

Posted on 13 April 2016 by Joanna Canham

In 2013, there were 45,525 new cases of lung cancer in the UK and it kills around 35,000 annually (Source: CRUK). Non-small cell lung cancer (NSCLC) accounts for around 87% […]